1.
Blood
; 144(3): 334-338, 2024 Jul 18.
Artículo
en Inglés
| MEDLINE
| ID: mdl-38657242
RESUMEN
ABSTRACT: In this retrospective study, chimeric antigen receptor T cells remained effective in patients with relapsed/refractory large B-cell lymphoma after prior exposure to bispecific antibodies (BsAbs) targeting different antigens. These results are relevant to clinical practice, particularly given the increasing use of BsAbs in earlier treatment lines.
